The significant growth of transaction volumes and the number of deals closed from 2017 to 2021 confirms the increasing importance of longevity in the US and Europe. For both markets, the number of deals almost … Read more
Genomics represents the most crucial pillar in the ‘OMX-space and is the largest subsector in the US and Europe (EUR 13.3bn vs. EUR 1.8bn). The second and third largest subsectors are microbiomics and proteomics for … Read more
A recent FCF Life Sciences analysis showed a significant decline in funding volumes for European life sciences markets in the first half of 2022 compared to 2021. This trend is now confirmed for the US … Read more
During the first six months of 2022, we find that the funding for life sciences markets declined significantly compared to 2021. The trend affects all relevant life sciences subsectors of Biotech, HealthTech, and MedTech. The … Read more
Venture capital deal volumes in the European life sciences sector reached a record-breaking level in 2021. However, financing volumes decreased significantly by 29% in the first four months of 2022 compared to 2021. Our … Read more
With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active corporate investor in the European life science market in the last five years. The only other investor having reached the top … Read more
It is no surprise that the top 5 European investors have shown significantly higher activities than US investors in Europe from 2017 to 2021. Nevertheless, US investors such as SOSV, Epidarex Capital, OrbiMed, and RA … Read more
The capital raised in BioTech IPOs declined heavily in Europe and the US. For Q4’21 – Q1’22, the amount of raised capital declined by 73 percent compared to Q4’20 – Q1’21 (from EUR 5,941m to … Read more
Investors from China continue to show exceptional interest in young life science companies based in Europe. Investments made by Chinese VCs have significantly grown 17-fold over the last five years (from EUR 34m in 2017 … Read more
Venture capital markets continue to show high interest in companies with a focus on regenerative medicine from Europe and the US. Since 2017 the market has shown exceptional growth, as funding volumes increased threefold to … Read more
